Gilead Sciences (GILD) Other Accumulated Expenses (2011 - 2026)

Gilead Sciences (GILD) has 12 years of Other Accumulated Expenses data on file, last reported at $3.4 billion in Q1 2026.

• Quarterly Other Accumulated Expenses fell 26.35% year-over-year to $3.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 billion (down 26.35% YoY) and the FY2025 annual result came in at $4.0 billion, down 27.65% from the prior year.
• Other Accumulated Expenses retreated to $3.4 billion in Q1 2026, from $4.0 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $5.9 billion in Q3 2023 to a low of $3.4 billion in Q1 2026.
• A 5-year average of $4.6 billion and a median of $4.5 billion in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses increased 12.01% — and 2025, when it slipped 27.65%.
• Tracing GILD's Other Accumulated Expenses over 5 years: stood at $4.6 billion in 2022, then rose by 12.01% to $5.1 billion in 2023, then increased by 6.51% to $5.5 billion in 2024, then declined by 27.65% to $4.0 billion in 2025, then fell by 14.01% to $3.4 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $3.4 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.